These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30306254)

  • 1. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.
    Steffen A; Holstiege J; Klimke K; Akmatov MK; Bätzing J
    Rheumatol Int; 2018 Nov; 38(11):2111-2120. PubMed ID: 30306254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
    Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
    JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Rheumatoid Arthritis and Drug Dispensing Patterns Among Medicaid and Medicaid-Medicare Dually Eligible Beneficiaries in Puerto Rico.
    Hernández-Muñoz JJ; Wei W; Sierra-Zorita R
    Arthritis Care Res (Hoboken); 2021 Feb; 73(2):199-206. PubMed ID: 32475025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
    Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization.
    Won S; Cho SK; Kim D; Han M; Lee J; Jang EJ; Sung YK; Bae SC
    Rheumatol Int; 2018 Apr; 38(4):649-656. PubMed ID: 29302803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study.
    Ferraz-Amaro I; Seoane-Mato D; Sánchez-Alonso F; Martín-Martínez MA;
    Rheumatol Int; 2015 Nov; 35(11):1825-36. PubMed ID: 26403284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids.
    George MD; Baker JF; Wallace B; Chen L; Wu Q; Xie F; Yun H; Curtis JR
    Arthritis Care Res (Hoboken); 2021 Nov; 73(11):1597-1605. PubMed ID: 32702188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
    Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
    J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980-1995: results from the National Ambulatory Medical Care Surveys.
    Ward MM
    J Rheumatol; 1999 Mar; 26(3):546-50. PubMed ID: 10090160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries.
    Kimsey L; Weissman JS; Patel A; Drew A; Koehlmoos T; Sparks JA
    Semin Arthritis Rheum; 2019 Apr; 48(5):821-827. PubMed ID: 30190154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Walsh JA; Pei S; Penmetsa GK; Sauer BC; Patil V; Walker JH; Clewell J; Douglas KM; Clegg DO; Cannon GW; Halwani A
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1218-1228. PubMed ID: 31663467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability in the prescription of biological drugs in rheumatoid arthritis in Spain: a multilevel analysis.
    López-Longo FJ; Seoane-Mato D; Martín-Martínez MA; Sánchez-Alonso F;
    Rheumatol Int; 2018 Apr; 38(4):589-598. PubMed ID: 29368023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.
    Sparks JA; Lesperance T; Accortt NA; Solomon DH
    Arthritis Care Res (Hoboken); 2019 Apr; 71(4):512-520. PubMed ID: 29799667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis.
    Yazdany J; Tonner C; Schmajuk G; Lin GA; Trivedi AN
    Arthritis Care Res (Hoboken); 2014 Oct; 66(10):1447-55. PubMed ID: 25244314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
    Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population.
    Crane MM; Juneja M; Allen J; Kurrasch RH; Chu ME; Quattrocchi E; Manson SC; Chang DJ
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1646-55. PubMed ID: 26097059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study.
    Huang Y; Agarwal SK; Chen H; Chatterjee S; Johnson ML; Aparasu RR
    Clin Ther; 2023 Sep; 45(9):e177-e186. PubMed ID: 37573225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of use of specialty services on disease-modifying antirheumatic drug use in the treatment of rheumatoid arthritis in an insured elderly population.
    Shipton D; Glazier RH; Guan J; Badley EM
    Med Care; 2004 Sep; 42(9):907-13. PubMed ID: 15319617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.